

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for August 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Accord Healthcare Inc.	ACH-Amlodipine	Norvasc	AMLODIPINE BESYLATE	2.5 mg	tablet	02419556
Marcan Pharmaceuticals Inc.	Mar-Doxepin	SINEQUAN	DOXEPIN HCL	75 mg	capsules	02559110
Marcan Pharmaceuticals Inc.	Mar-Doxepin	SINEQUAN	DOXEPIN HCL	100 mg	capsules	02559129

Jamp Pharma Corporation	Jamp Lisdexamfetamine	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	70 mg	capsules	02535181
Mantra Pharma Inc	M-Progesterone	Prometrium	PROGESTERONE	100 mg	capsule	02551268
Jamp Pharma Corporation	Jamp Zopiclone	Imovane	ZOPICLONE	5 mg	Tablet	02549298